Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT01959633 | Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation(VEMUPLINT) | completed | Phase 1 / Phase 2 | 11 | Fondazione Melanoma OnlusOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02381314 | Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | completed | Phase 1 | 24 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02482532 | Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma(MARVSmALo) | completed | Phase 1 | 7 | Gary DoolittleOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT03278665 | 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy(SENSITIZE) | completed | Phase 1 / Phase 2 | 40 | 4SC AGINDUSTRY | 2 | Feb 4, 2022 | clinicaltrials |
| NCT02225366 | Intratumoral Injections of LL37 for Melanoma | completed | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT00730639 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies(MDX1106-03) | completed | Phase 1 | 395 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 3, 2021 | clinicaltrials |
| NCT02716948 | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 27 | University of LouisvilleOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02983006 | Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 | 12 | NYU Langone HealthOTHER | 1 | Oct 18, 2021 | clinicaltrials |
| NCT02574377 | myDC/pDC in Stage III Melanoma Patients | completed | Phase 1 / Phase 2 | 30 | Radboud University Medical CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01497808 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | completed | Phase 1 / Phase 2 | 22 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02112032 | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | completed | Phase 1 | 43 | Hassane M. Zarour, MDOTHER | 1 | May 5, 2021 | clinicaltrials |
| NCT00118274 | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 170 | Craig L Slingluff, JrOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02110355 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | completed | Phase 1 | 31 | Kartos Therapeutics, Inc.INDUSTRY | 2 | Mar 26, 2021 | clinicaltrials |
| NCT00303251 | Safety of TKI258 in Advanced/Metastatic Melanoma Subjects | completed | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 11, 2021 | clinicaltrials |
| NCT00258687 | Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT00398450 | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | University of California, San DiegoOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02897765 | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | completed | Phase 1 | 34 | BioNTech US Inc.INDUSTRY | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02339324 | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | completed | Phase 1 | 31 | Yana NajjarOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02902042 | Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma(IMMU-TARGET) | completed | Phase 1 / Phase 2 | 16 | Prof. Dr. med. Dirk SchadendorfOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01149343 | Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer | completed | Phase 1 | 107 | GlaxoSmithKlineINDUSTRY | 6 | Nov 20, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02771340 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | completed | Phase 1 | 10 | Iconic Therapeutics, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | completed | Phase 1 | 149 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 10, 2020 | clinicaltrials |
| NCT00005617 | Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00090896 | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | completed | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01005472 | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00498979 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | completed | Phase 1 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | completed | Phase 1 | 84 | Immunocore LtdINDUSTRY | 2 | Jul 8, 2020 | clinicaltrials |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma(X4P-001-MELA) | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | completed | Phase 1 | 39 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01897116 | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | completed | Phase 1 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 31, 2022source: clinicaltrials